trial

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

NCTId NCT02634684
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 82 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2020-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
82 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2014-07-01
Primary completion
2020-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Dextroamphetamine

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Neal R. Swerdlow, M.D., Ph.D.Principal Investigator

Sites

1 total
San Diego, United States

Linked catalysts

1
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia. — primary completion2020-08

Facts & assertions

4 sourced
Enrollment
82
Phase
PHASE2
Primary Completion Date
2020-08
Status
COMPLETED
relationships
The graph out of here
drug
Dextroamphetamine
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication
Mental Disorders
indication
investigator
Neal R. Swerdlow, M.D., Ph.D.
person